A phase IIa clinical trial of a human CCR2 antagonist (MLN1202) in patients with active rheumatoid arthritis found that treatment with the CCR2 antagonist reduced free CCR2 levels on CD14+ monocytes by at least 57% and up to 94%. Here, CD14 is linked to rheumatoid arthritis.